SCHEMBL3528519

SCHEMBL3528519

Cn1c(C2CC2)c(Br)c(=O)n1-c1cccc(F)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 1/20 0.39
HSD11B1 P28845 2/20 0.38
FAAH O00519 1/20 0.38
MGLL Q99685 1/20 0.38
ALOX5 P09917 2/20 0.38
ALDH1A1 P00352 3/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
TSHR P16473 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
CCR3 P51677 1/20 0.36
ESR1 P03372 1/20 0.35
ESR2 Q92731 1/20 0.35
METAP2 P50579 1/20 0.35
MPI P34949 1/20 0.35
FADS1 O60427 1/20 0.34
ACHE P22303 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3532450 0.85 HSD11B1 (0.42) HTR7HSD11B1FAAHMGLLALOX5
SCHEMBL3535479 0.85 BCHE (0.39) HSD11B1MGLLALOX5ALDH1A1MEN1
SCHEMBL3538283 0.85 HSD11B1 (0.37) HSD11B1FAAHMGLLALOX5ALDH1A1
SCHEMBL3531196 0.84 ALDH1A1 (0.44) HTR7ALOX5ALDH1A1TSHRMEN1
SCHEMBL3527822 0.83 MEN1 (0.37) HTR7HSD11B1ALDH1A1L3MBTL1TSHR
SCHEMBL3526100 0.83 ALDH1A1 (0.44) HSD11B1ALDH1A1TSHRMEN1KMT2A
SCHEMBL3531287 0.79 HSD11B1 (0.38) HSD11B1ALDH1A1L3MBTL1
SCHEMBL3533829 0.79 L3MBTL1 (0.34) HTR7HSD11B1L3MBTL1
SCHEMBL3528198 0.78 SMN1; SMN2 (0.43) HSD11B1ALDH1A1TSHRMEN1KMT2A
SCHEMBL3532708 0.76 HSD11B1 (0.39) HSD11B1MGLLMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652057-B2 Pyrazolones as 11b-HSD1 inhibitors for diabetes HOFFMAN-LA ROCHE INC. (US) 2010-01-26 US disclosed
EP-1924562-A2 PYRAZOLONE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-05-28 EP disclosed
WO-2007025880-A2 PYRAZOLONE DERIVATIVES AS 11-BETA HSD1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-03-08 WO disclosed
US-20070049574-A1 New pyrazolones as 11b-HSD1 inhibitors for diabetes F. HOFFMANN-LA ROCHE AG (CH) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049574-A1 New pyrazolones as 11b-HSD1 inhibitors for diabetes HSD11B1, HSD17B1, HSD17B7 HTR7 1546/4885HSD11B1 1/4885FAAH 2720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.